期刊
ALLERGY
卷 73, 期 1, 页码 106-114出版社
WILEY
DOI: 10.1111/all.13256
关键词
allergy; galectin-1; immune regulation; mast cells; specific immunotherapy
资金
- Innovation of Science and Technology Commission of Shenzhen Municipality [JCYJ20140418095735611, JCYJ20160422101725667, JCYJ20160429091935720, ZDSYS201506050935272]
- Guangdong Scientific Technology Foundation [2014A020212422]
- Natural Science Foundation of China [81373176, 31400856, 81503623, 81571790, 81501573]
Background and AimsMast cell activation interferes with the effects of allergen-specific immunotherapy (SIT). Galectin-1 (Gal-1) is capable of regulating immune cells' functions. This study tests the hypothesis that administration of Gal-1 promotes and prolongs the efficacy of SIT via suppressing mast cell activation. MethodsAn intestinal allergy mouse model was developed. The coadministration of SIT and Gal-1 on suppression of the allergic responses, prevention of mast cell activation, and generation of antigen-specific regulatory T cells (Treg) in the intestine was observed in sensitized mice. ResultsThe coadministration of Gal-1 and SIT markedly suppressed the allergic responses in the mouse intestine vs the use of either SIT alone or Gal-1 alone. The Gal-1 binds to the IgE/FcRI complexes on the surface of mast cells to prevent mast cell activation during SIT. Gal-1 promoted the SIT-generated allergen-specific Tregs in the intestine of sensitized mice. Coadministration of Gal-1 and SIT significantly enhanced the efficacy of immunotherapy in suppressing allergic responses in the intestine, which lasted for at least for 12months. ConclusionsLong-term effects of specific immunotherapy on intestinal allergy can be achieved with Gal-1/SIT therapy by inhibiting mast cell activation and facilitating Treg development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据